Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 3/20 | 0.62 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.62 |
| ▸ | ITGAL | P20701 | 3/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187470 | 0.89 | ITGB2 (0.49) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL1132649 | 0.87 | ITGB2 (0.57) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL1133307 | 0.87 | ITGB2 (0.57) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL14028689 | 0.87 | ITGB2 (0.57) | ITGB2ICAM1ITGALCA1CA2 | |
| Hydrochloric Acid SCHEMBL27702031 | 0.87 | ITGB2 (0.60) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL12979930 | 0.86 | ITGB2 (0.47) | ITGB2ICAM1ITGALSLC6A5CYP3A4 | |
| SCHEMBL888751 | 0.86 | ITGB2 (0.47) | ITGB2ICAM1ITGALCYP3A4SLC7A5 | |
| SCHEMBL10122812 | 0.86 | ITGB2 (0.47) | ITGB2ICAM1ITGALCYP3A4SLC7A5 | |
| SCHEMBL7438987 | 0.86 | ITGB2 (0.54) | ITGB2ICAM1ITGALCA1CA2 | |
| SCHEMBL28684251 | 0.85 | ITGB2 (0.56) | ITGB2ICAM1ITGALCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | DOLLE ROLAND E (US) | 2004-01-15 | — | — | US | disclosed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | disclosed |
| EP-0623592-B1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | VERTEX PHARMA (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | IL1B, IL1A, IL1RN | ITGB2 1401/4885ICAM1 151/4885ITGAL 1591/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | ITGB2 4484/4885ICAM1 2984/4885ITGAL 4111/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | ITGB2 4484/4885ICAM1 2984/4885ITGAL 4111/4885 |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ITGB2 3553/4885ICAM1 2369/4885ITGAL 3697/4885 |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ITGB2 2360/4885ICAM1 556/4885ITGAL 1876/4885 |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ITGB2 2360/4885ICAM1 556/4885ITGAL 1876/4885 |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ITGB2 2360/4885ICAM1 556/4885ITGAL 1876/4885 |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ITGB2 2360/4885ICAM1 556/4885ITGAL 1876/4885 |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ITGB2 2360/4885ICAM1 556/4885ITGAL 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.